Altered peptide ligand modulation of experimental allergic encephalomyelitis: Immune responses within the CNS

Journal of Neuroimmunology

Volumn 81, Issue 1-2, 1998, Pages 1-13

  Santambrogio, Laura ^a,b   Lees, Marjorie B ^a,b   Sobel, Raymond A ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Cytokines; EAE; Neuroimmunology; T lymphocytes

Indexed keywords

PROTEOLIPID;

ALLERGIC ENCEPHALITIS; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; BRAIN PROTECTION; CROSS REACTION; FEMALE; HOST RESISTANCE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS; AUTOIMMUNE DISEASES; BRAIN; CRICETINAE; CROSS REACTIONS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNIZATION; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; INTERFERON TYPE II; LIGANDS; LYMPHOCYTE COUNT; MICE; MUTAGENESIS, SITE-DIRECTED; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031808897     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00138-0     Document Type: Article

References (58)

1. Ahuja S.S., Paliogianni F., Yamada H., Balow J.E., Boumpas D.T. Effects of transforming growth factor-β on early and late activation events in human T cells. J. Immunol. 150:1993;3109-3118.
2. Boehme S.A., Lenardo M.J. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 23:1993;1552-1560.
3. Brocke S., Gijbels K., Allegretta M., Fierber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D., Veromaa T., Weisman A., Guar A., Conlon P., Ling N., Fairchild P.J., Wraith D.C., O'Garra A., Fathman C.G., Steinman L. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:1996;343-346.
4. Celada A., Maki R.A. Transforming growth factor β enhances the M-CSF and GM-CSF-stimulated proliferation of macrophages. J. Immunol. 148:1992;1102-1105.
5. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochem. 162:1987;156-159.
6. Crisi G.M., Santambrogio L., Hochwald G.M., Smith S.R., Carlino J.A., Thorbecke G.J. Staphylococcal enterotoxin B and tumor-necrosis factor-α-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-β and interleukin-10. Eur. J. Immunol. 25:1995;3035-3040.
7. Dore-Duffy R., Balabanov R., Washington R., Swanborg R.H. Transforming growth factor β1 inhibits cytokine-induced CNS endothelial cell activation. Molec. Chem. Neuropathol. 22:1994;161-175.
8. Evavold B.D., Sloan-Lancaster J., Wilson K.J., Rothbard J.B., Allen P.M. Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Immunity. 2:1995;655-663.
9. Fabry Z., Topham D.J., Fee D., Herlein J., Carlino J.A., Hart M.N., Sriram S. TGF-β decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J. Immunol. 155:1995;325-332.
10. Finkelman F. Relationships among antigen presentation, cytokines, immune deviation and autoimmune disease. J. Exp. Med. 182:1995;279-282.
11. Franco A., Southwood S., Arrhenius T., Kuchroo V.K., Grey H.M., Sette A., Ishioka G.Y. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur. J. Immunol. 24:1994;940-946.
12. Fujinami R.S., Oldstone M.B.A. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science. 230:1985;1043-1045.
13. Gamble J.R., Vadas M.A. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-β J. Immunol. 146:1991;1149-1154.
14. Gaur A., Boehme S.A., Chalmers D., Crowe P.D., Pahuja A., Ling N., Brocke S., Steinman L., Conlon P.J. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J. Neuroimmunol. 74:1997;149-158.
15. Greer J.M., Kuchroo V.K., Sobel R.A., Lees M.B. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residue 178-191) for SJL mice. J. Immunol. 149:1992;783-788.
16. Greer J.M., Sobel R.A., Sette A., Southwood S., Lees M.B., Kuchroo V.K. Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J. Immunol. 156:1996;371-379.
17. Harris D.P., Vordermeier H.-M., Singh M., Moreno C., Jurcevic S., Ivanyi J. Cross-recognition by T cells of an epitope shared by two unrelated mycobacterial antigens. Eur. J. Immunol. 25:1995;3173-3179.
18. Hurwitz A.A., Lyman W.D., Berman J.W. Tumor necrosis factor α and transforming growth factor β upregulate astrocyte expression of monocyte chemoattractant protein-1. J. Neuroimmunol. 57:1995;193-198.
19. Irani D.N., Griffin D.E. Isolation of brain parenchymal lymphocytes for flow cytometric analysis. J. Immunol. Meth. 139:1991;223-231.
20. Karin N., Mitchell D.J., Brocke S., Ling N., Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. 180:1994;2227-2237.
21. + suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-β J. Immunol. 146:1991;1163-1168.
22. Kennedy M.K., Torrance D.S., Picha K.S., Mohler K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:1992;2496-2505.
23. Kitagawa K., Sinoway M.P., Yang C., Gould R.M., Colman D.R. A proteolipid protein gene family: expression in sharks and rays and possible evolution from an ancestral gene encoding a pore-forming polypeptide. Neuron. 11:1993;433-448.
24. Kuchroo V.K., Greer J.M., Kaul D., Ishioka G., Franco A., Sette A., Sobel R.A., Lees M.B. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153:1994;3326-3336.
25. Kumar V., Bhardwaj V., Soares L., Alexander L., Sette A., Sercarz E. Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon-γ by T cells. Proc. Natl. Acad. Sci. USA. 92:1995;9510-9514.
26. Kumar V., Urban J.L., Horvath S.J., Hood L. Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis. Immunology. 87:1990;1337-1341.
27. Link J., Söderström M., Olsson T., Höjeberg B., Ljungdahl Å., Link H. Increased transforming growth factor-β, interleukin-4, and interferon-γ in multiple sclerosis. Ann. Neurol. 36:1994;379-386.
28. Madrenas J., Wange R.L., Wang J.L., Isakov N., Samelson L.E., Germain R.W. (Zeta) phosphorylation without ZAP-70 activation induced by TCR antagonists or partial antagonists. Science. 267:1995;515-518.
29. Maeda H., Kuwahara H., Ichimura Y., Ohtsuki M., Kurakata S., Shiraishi A. TGF-β enhanced macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol. 155:1995;4926-4932.
30. + effector T cells in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 75:1997;156-162.
31. Miller A., Al-Sabbagh A., Santos L.M., Das M.P., Weiner H.L. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immunol. 151:1993;7307-7315.
32. Mokhtarian F., Shi Y., Shirazian D., Morgante L., Miller A., Grob D. Defective production of anti-inflammatory cytokine, TGF-β by T cell lines of patients with active multiple sclerosis. J. Immunol. 152:1994;6003-6010.
33. Nicholson L.B., Greer J.M., Sobel R.A., Lees M.B., Kuchroo V.K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity. 3:1995;397-405.
34. Racke M.K., Burnett D., Pak S.-H., Albert P.S., Cannella B., Raine C.S., McFarlin D.E., Scott D.E. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J. Immunol. 154:1995;450-458.
35. Racke M.K., Cannella B., Albert P., Sporn M., Raine C.S., McFarlin D.E. Evidence of endogenous regulatory function of transforming growth factor-β1 in experimental allergic encephalomyelitis. Intl. Immunol. 4:1992;615-620.
36. 1. J. Immunol. 146:1991;3012-3017.
37. Renno T., Lin J.-Y., Piccirillo C., Antel J., Owens T. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SJL/J mice. J. Neuroimmunol. 49:1994;1-7.
38. Ruddle N.H., Berman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1990;1193-1200.
39. Samson M.F., Smilek D.E. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J. Immunol. 155:1995;2737-2746.
40. Santambrogio L., Hochwald G.M., Saxena B., Leu C.H., Martz J.E., Carlino J.A., Ruddle N.H., Palladino M.A., Gold L.I., Thorbecke G.J. Studies on the mechanisms by which transforming growth factor-β (TGF-β) protects against allergic encephalomyelitis. J. Immunol. 151:1993;1116-1127.
41. Santambrogio L., Crisi G.M., Leu J., Hochwald G.M., Ryan T., Thorbecke G.J. Tolerogenic forms of auto-antigens and cytokines in the induction of resistance to experimental allergic encephalomyelitis. J. Neuroimmunol. 58:1995;211-222.
42. Saoudi A., Simmonds S., Huitinga I., Mason D. Prevention of experimental allergic encephalomyelitis in rats targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells. J. Exp. Med. 182:1995;279-282.
43. 2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-γ and tumor necrosis factor-α J. Neuroimmunol. 27:1990;41-47.
44. Sloan-Lancaster J., Allen P. Significance of T cell stimulation by altered peptide ligands in T cell biology. Curr. Opin. Immunol. 7:1995;103-109.
45. Smilek D.E., Wraith D.C., Hodgkinson S., Dwivedy S., Steinman L., McDevitt H.O. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Immunology. 88:1991;9633-9637.
46. Sobel R.A., Kuchroo V.K. The immunopathology of acute experimental allergic encephalomyelitis induced with myelin proteolipid protein:T cell receptors in inflammatory lesions. J. Immunol. 149:1992;1444-1451.
47. Stavnezer J. Regulation of antibody production and class switching by TGFβ J. Immunol. 155:1995;1647-1651.
48. Steinman L. Escape from 'horror autotoxicus': pathogenesis and treatment of autoimmune disease. Cell. 80:1995;7-10.
49. Stevens D.E., Gould K.E., Swanborg R.H. Transforming growth factor-β1 inhibits tumor necrosis factor-α/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J. Neuroimmunol. 51:1994;77-83.
50. Sun D., Coleclough C., Hu X.-S. Heterogeneity of rat encephalitogenic T cells elicited by variants of the myelin basic protein (68-86) peptide. Eur. J. Immunol. 25:1995;1687-1692.
51. Suzumura A., Sawada M., Yamamoto H., Marunouchi T. Transforming growth factor-β suppresses activation and proliferation of microglia in vitro. J. Immunol. 151:1993;2150-2158.
52. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142:1989;1523-1527.
53. Turner M., Chantry D., Feldmann M. Transforming growth factor β induces the production of interleukin 6 by human peripheral blood mononuclear cells. Cytokine. 2:1990;211-216.
54. + T cells. J. Immunol. 150:1993;5519-5528.
55. Windhagen A., Scholz C., Höllsberg P., Fukaura H., Sette A., Hafler D.A. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity. 2:1995;373-380.
56. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell- mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 80:1995;695-705.
57. Yan Y., Lagenaur C., Narayanan V. Molecular cloning of M6: identification of a PLP/DM20 gene family. Neuron. 11:1993;423-431.
58. Zhang X., Giangreco L., Broome H.E., Dargan C.M., Swain S.L. Control of CD4 effector fate: transforming growth factor β1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J. Exp. Med. 182:1995;699-709.